Cargando…
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering
A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen–antibody immune complexes, which escape from lysosomal deg...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067469/ https://www.ncbi.nlm.nih.gov/pubmed/35482905 http://dx.doi.org/10.1080/19420862.2022.2068213 |
_version_ | 1784700011322277888 |
---|---|
author | Hori, Yuji Ohmine, Ken Katada, Hitoshi Noguchi, Yuki Sato, Kazuki Nambu, Takeru Adeline, Lam Runyi Wan, Gan Siok Haraya, Kenta Ozeki, Kazuhisa Nanami, Masahiko Tachibana, Tatsuhiko Sampei, Zenjiro Kuramochi, Taichi Nezu, Junichi Hattori, Kunihiro Igawa, Tomoyuki |
author_facet | Hori, Yuji Ohmine, Ken Katada, Hitoshi Noguchi, Yuki Sato, Kazuki Nambu, Takeru Adeline, Lam Runyi Wan, Gan Siok Haraya, Kenta Ozeki, Kazuhisa Nanami, Masahiko Tachibana, Tatsuhiko Sampei, Zenjiro Kuramochi, Taichi Nezu, Junichi Hattori, Kunihiro Igawa, Tomoyuki |
author_sort | Hori, Yuji |
collection | PubMed |
description | A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen–antibody immune complexes, which escape from lysosomal degradation using neonatal Fc receptor (FcRn)-mediated recycling. To address this, we developed an antigen-sweeping antibody that combines pH-dependent antigen binding and Fc engineering to enhance Fc receptor binding. The sweeping antibody actively eliminates the plasma antigens by increasing the cellular uptake of the immune complex and dissociating the antigens in the acidic endosome for degradation. Strong antigen sweeping can reduce the dosage, potentially achieve higher efficacy, and expand the scope of antigen space available for targeting by antibodies. In this study, to further improve the sweeping efficacy, we developed a novel antibody Fc variant by enhancing Fcγ receptor IIb (FcγRIIb) binding and modulating charge characteristics for increased cellular uptake of the immune complex, together with enhancing FcRn binding for efficient salvage of the antigen-free antibodies. Our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with antibody pharmacokinetics comparable to a wild-type human IgG(1) antibody. The positive-charge substitutions enhanced uptake of the immune complex by FcγRIIb-expressing cells in vitro, which was completely inhibited by an anti-FcγRIIb antibody. This suggests that the strong in vivo sweeping efficacy improved by the charge engineering is more likely achieved by FcγRIIb-dependent uptake of the immune complex rather than nonspecific uptake. We expect this novel Fc engineering can maximize the antigen sweeping efficacy even in humans and create novel therapeutic antibodies that meet unmet medical needs for patients. |
format | Online Article Text |
id | pubmed-9067469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-90674692022-05-05 Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering Hori, Yuji Ohmine, Ken Katada, Hitoshi Noguchi, Yuki Sato, Kazuki Nambu, Takeru Adeline, Lam Runyi Wan, Gan Siok Haraya, Kenta Ozeki, Kazuhisa Nanami, Masahiko Tachibana, Tatsuhiko Sampei, Zenjiro Kuramochi, Taichi Nezu, Junichi Hattori, Kunihiro Igawa, Tomoyuki MAbs Report A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen–antibody immune complexes, which escape from lysosomal degradation using neonatal Fc receptor (FcRn)-mediated recycling. To address this, we developed an antigen-sweeping antibody that combines pH-dependent antigen binding and Fc engineering to enhance Fc receptor binding. The sweeping antibody actively eliminates the plasma antigens by increasing the cellular uptake of the immune complex and dissociating the antigens in the acidic endosome for degradation. Strong antigen sweeping can reduce the dosage, potentially achieve higher efficacy, and expand the scope of antigen space available for targeting by antibodies. In this study, to further improve the sweeping efficacy, we developed a novel antibody Fc variant by enhancing Fcγ receptor IIb (FcγRIIb) binding and modulating charge characteristics for increased cellular uptake of the immune complex, together with enhancing FcRn binding for efficient salvage of the antigen-free antibodies. Our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with antibody pharmacokinetics comparable to a wild-type human IgG(1) antibody. The positive-charge substitutions enhanced uptake of the immune complex by FcγRIIb-expressing cells in vitro, which was completely inhibited by an anti-FcγRIIb antibody. This suggests that the strong in vivo sweeping efficacy improved by the charge engineering is more likely achieved by FcγRIIb-dependent uptake of the immune complex rather than nonspecific uptake. We expect this novel Fc engineering can maximize the antigen sweeping efficacy even in humans and create novel therapeutic antibodies that meet unmet medical needs for patients. Taylor & Francis 2022-04-28 /pmc/articles/PMC9067469/ /pubmed/35482905 http://dx.doi.org/10.1080/19420862.2022.2068213 Text en © 2022 Chugai Pharmaceutical Co., Ltd. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Hori, Yuji Ohmine, Ken Katada, Hitoshi Noguchi, Yuki Sato, Kazuki Nambu, Takeru Adeline, Lam Runyi Wan, Gan Siok Haraya, Kenta Ozeki, Kazuhisa Nanami, Masahiko Tachibana, Tatsuhiko Sampei, Zenjiro Kuramochi, Taichi Nezu, Junichi Hattori, Kunihiro Igawa, Tomoyuki Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering |
title | Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering |
title_full | Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering |
title_fullStr | Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering |
title_full_unstemmed | Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering |
title_short | Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering |
title_sort | elimination of plasma soluble antigen in cynomolgus monkeys by combining ph-dependent antigen binding and novel fc engineering |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067469/ https://www.ncbi.nlm.nih.gov/pubmed/35482905 http://dx.doi.org/10.1080/19420862.2022.2068213 |
work_keys_str_mv | AT horiyuji eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT ohmineken eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT katadahitoshi eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT noguchiyuki eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT satokazuki eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT nambutakeru eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT adelinelamrunyi eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT wangansiok eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT harayakenta eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT ozekikazuhisa eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT nanamimasahiko eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT tachibanatatsuhiko eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT sampeizenjiro eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT kuramochitaichi eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT nezujunichi eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT hattorikunihiro eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering AT igawatomoyuki eliminationofplasmasolubleantigenincynomolgusmonkeysbycombiningphdependentantigenbindingandnovelfcengineering |